表紙
市場調査レポート

角膜移植片拒絶反応 : パイプライン分析

Corneal Graft Rejection - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 253680
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
角膜移植片拒絶反応 : パイプライン分析 Corneal Graft Rejection - Pipeline Review, H1 2016
出版日: 2016年03月22日 ページ情報: 英文 44 Pages
概要

角膜移植では損傷した角膜組織を健康な角膜と交換しますが、時として、人体の免疫系が新しい組織を拒絶する場合があります。拒絶反応は移植してから数ヵ月、さらには数年経って発症することがあります。主な症状として、目の充血(赤目)や眼通、炎症、羞明、視力低下などが挙げられます。主な治療法にはステロイド剤や免疫抑制剤などがあります。

当レポートでは、世界各国での角膜移植後拒絶反応治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

角膜移植片拒絶反応の概要

治療薬の開発

  • 角膜移植片拒絶反応向けパイプライン製品:概要
  • 角膜移植片拒絶反応向けパイプライン製品:比較分析

各企業で開発中の角膜移植片拒絶反応向け治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

角膜移植片拒絶反応向け治療薬:開発中の製品の一覧(企業別)

角膜移植片拒絶反応向け治療薬の開発に従事している企業

  • Circadian Technologies Limited
  • Oxford BioMedica Plc

角膜移植片拒絶反応:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • Cyndacel-M
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • EncorStat
  • GB-301
  • 角膜移植片拒絶反応向け間質細胞療法
  • VGX-100

角膜移植片拒絶反応向け治療薬:パイプライン製品の最新動向

角膜移植片拒絶反応向け治療薬:休止中のプロジェクト

角膜移植片拒絶反応関連の製品開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7786IDB

Summary

Global Markets Direct's, 'Corneal Graft Rejection - Pipeline Review, H1 2016', provides an overview of the Corneal Graft Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Corneal Graft Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Corneal Graft Rejection and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Corneal Graft Rejection
  • The report reviews pipeline therapeutics for Corneal Graft Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Corneal Graft Rejection therapeutics and enlists all their major and minor projects
  • The report assesses Corneal Graft Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Corneal Graft Rejection

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Corneal Graft Rejection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Corneal Graft Rejection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Corneal Graft Rejection Overview
  • Therapeutics Development
    • Pipeline Products for Corneal Graft Rejection - Overview
  • Corneal Graft Rejection - Therapeutics under Development by Companies
  • Corneal Graft Rejection - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Corneal Graft Rejection - Products under Development by Companies
  • Corneal Graft Rejection - Companies Involved in Therapeutics Development
    • Circadian Technologies Limited
    • Gene Signal International SA
    • Oxford BioMedica Plc
    • Santen Pharmaceutical Co., Ltd.
  • Corneal Graft Rejection - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aganirsen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GB-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OXB-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stromal Cell Therapy for Corneal Graft Rejection - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VGX-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Corneal Graft Rejection - Recent Pipeline Updates
  • Corneal Graft Rejection - Dormant Projects
  • Corneal Graft Rejection - Product Development Milestones
    • Featured News & Press Releases
      • Jan 30, 2012: VGX-100 Identified As Potential New Therapy For Improving Corneal Graft Survival
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Corneal Graft Rejection, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Corneal Graft Rejection - Pipeline by Circadian Technologies Limited, H1 2016
  • Corneal Graft Rejection - Pipeline by Gene Signal International SA, H1 2016
  • Corneal Graft Rejection - Pipeline by Oxford BioMedica Plc, H1 2016
  • Corneal Graft Rejection - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Corneal Graft Rejection Therapeutics - Recent Pipeline Updates, H1 2016
  • Corneal Graft Rejection - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Corneal Graft Rejection, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top